Post Reply
10641-10660 of 10899
yes please..... how about $1.5
Looks like it will surpass $1.20 this week! So fierce!
It surged after it said it had been granted a U.S. patent for its Biolimus A9 drug. The drug can be used in various medical treatments including the treatment of vascular injuries, inflammation and organ transplant rejection, the company said in a statement to the stock exchange on Wednesday.
Moreover, Biosensors has been added to the MSCI Small Cap Index Series. which will take effect after the market closes on May 31. Inclusion will gain more exposure from foreign investors.
It also received a $5m payment from licensee Terumo Corp after both reached the final stage in a deal to license Biosensor's drug technologies.
high can get higher...
maybe they will test the 95 mark tomorrow....
must jump higher......
ha ha ha... yeah, this counter always give surprises, no doubts..
K.H.Neo, forget it, it is 0.92 high today, not need to buy now.. you should cash in while it was 0.75-0.78 last two weeks, when it runs so much, forget it ba..
Bro knightrider can vest @ this counter or is too high now pls advise thanks
this salted fish is swimming again.....what next?
Cheong now, above 0.9c
Somehow this counter seems a little too noisy now.
sound good news to me... a call on up trend.....and analyst ask "how soon" on CE apporval.....
once approve....it will become take over target for Big Boys......
Having just listened to Xtent's conference call (q107 results), questions were thrown by analysts as to how soon, Biosensors CE mark approval will be. This is important to Xtent, as they are using the same polymer/drug as Biosensors.
The reply by Xtent's CEO is that Biosenors's mgmt remains confident that they are very closed to the CE Mark, and that they are very confident of Biosensors's polymer/drug technology.
It has been a 2 yr waiting period so far for Biosensors (application for CE mark was in april 05), with other companies getting their approval within 1- 1 1/2 yrs. It seems that the CE mark approval authority in Europe are decentralised, and it is the luck of the draw, which Notifying Body (CE mark approval authority) is doing your approval.
My own suspicion is probably that Biolimus is a new drug, and therefore the authorities are more cautious in granting approval. However, recent toxicity tests caried out on Biolimus has shown it to be very safe, and this might be a factor in hastening the approval.
Also, Xtent's CEO has highlighted the upcoming EURO PCR meet this 22nd may, that some new interesting animal data will be presented by a Mr. Andy Carter (I think that is the name).
My thinking is that Biosensors has been highlighting the healing properties of Biolimus (better endothelialisation), as compared to current commercial existing drugs, and which will therefore reduced the problem of stent thrombosis.
As usual, trade with caution - a very volatile stock, with huge zig-zag swings.
The technical picture has indeed look better, but I would not be convinced until it is able to closed above 0.875, during the next few days, which represents the closest significant resistance, and which will also mean that the stock has risen above its long term moving ave of 200 days.
I am talking here, abt the sustainability of the uptrend (if proven to be so). Also, even if it clears 0.875, the next seemingly insurmountable resistance is at 0.995-1.01, which it has not cleared for the last 1 yr, remains difficult.
The good thing about the recent movement is that Biosensors has found quite strong support at 0.75, where it has bounced off that price quite a few times.
TA signals have reversed. Now looks bullish.
Acc/Dist and Chaikin both uptrending. Price has also cut the upper bollinger band which is a good sign.
slowly lar.... like what JackJames mentioned ....they will release their results some time next week.... as usual how good can it get.... 
watch out $1.00 coming soon...........
this counter sometime the vol thin.... like that also can inculde into index...
more news to come?
It is precisely, that the medical community is worried about the safety of existing stents that, 2nd generation stents like Biosensors will become more interesting.
However, it will take a long time, before its product is released into the mkt.
Current newsflow on Biosensors include its inclusion into the MSCI small cap index on 30th may 2007, the coming international Euro meet on 22nd may - 25 may, whereby, its technology will be discussed more in detail among its licensee, Xtent, Devaxx.
very interesting, 1200 lots buy up, then, 1000 lots sell down, ha ha... exchange hands man..
not vested.
bengster, you are not so lucky today, BIOSENSOR is UP 0.85 ! cool....
http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070517:MTFH11233_2007-05-17_08-41-50_N17305206&type=comktNews&rpc=44
I knew it. All major stent players share price dropped. Go to Yahoo finance check JNJ, BSX, ABT and MDT. Wonder if Biosensors will be sold down tomorrow. Good luck